You can cancel at any time. John is the Chief Marketing Officer at Wealth Morning. Wealth Morning is an investment resource created exclusively for investors and those looking for opportunities under the radar. PEB is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year. Debt Level: PEB's debt to equity ratio (2.6%) is considered satisfactory. In the chart below below, we can see that institutional investors have bought into the company. The ability for non-invasive, regular testing will benefit both patients and physicians in the long-run. Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United Stat, Unless specified all financial data is based on a yearly period but updated quarterly. What is Pacific Edge current dividend yield, its reliability and sustainability? (28.5x) compared to the XO Biotechs industry average (6.4x). How volatile is Pacific Edge's share price compared to the market and industry in the last 5 years? Pacific Edge is a smaller company with a market capitalization of NZ$151m, so it may still be flying under the radar of many institutional investors. Pacific Edge is a New Zealand based biomedical company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. ... Pacific Genomics, Pacific Edge Biotechnology TAGS biomarkers. to determine if its dividend payments are covered by earnings. PACIFIC EDGE BIOTECHNOLOGY LIMITED (PEB) Profile, former (or subsequent) names, directors transactions, unclaimed dividends, registry details Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. They specialise in genetic-biomarker testing known as CxBladder. They specialise in genetic-biomarker testing known as CxBladder. Read More News & Events Latest news updates, announcements and calendar of events. Quality Earnings: PEB is currently unprofitable. It has a return on equity of –130.21%, which indicates that the company has a history of being unprofitable. High Dividend: Unable to evaluate PEB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts. Pacific Edge Ltd. company facts, information and stock details by MarketWatch. How is Pacific Edge forecast to perform in the next 1 to 3 years based on estimates from 3 analysts? Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Volatility Over Time: PEB's weekly volatility has decreased from 22% to 8% over the past year, but is still higher than 75% of NZ stocks. Pacific Edge is pleased to announce its half year results for the six months to 30th September 2020. High ROE: PEB has a negative Return on Equity (-54.45%), as it is currently unprofitable. They provide a diagnostic service through their facilities in New Zealand and the United States as well as selected partners in Europe and Australia. for more than a year based on its current. Growing Profit Margin: PEB is currently unprofitable. This positive development reinforces a string of successful moves in recent months: ANZ New Zealand Investments is the country’s largest fund-manager — with $33 billion under management. Pacific Edge Limited [NZX: PEB] has benefited from a burst of optimism today, causing the share price to leap over 18%. Dec. 28, 2020 — Chemists have made a discovery that supports a surprising new view of how life originated on our planet. However, for prospective investors, some caution is still needed. Top Fundamentals. Last price $ 1.22. Pacific Edge Biotechnology Limited PEB-NZ Add to Portfolio. Future Dividend Coverage: No need to calculate the sustainability of PEB's dividend in 3 years as they are not forecast to pay a notable one for the NZ market. Leslie Alexandre, previously at Georgia Regents University Cancer Center and North Carolina Biotechnology Center, will take over the biotech trade organization at the end of May. (2018). Earnings Trend: PEB is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year. Level the playing field with access to the latest investment research. in the past year, with total shares outstanding growing by 5.3%. Dec 21st, 2020 End-of-day quote New Zealand Stock Exchange - 11/27: 0.69: NZD : 0.00%: 11/02: Australia shares make cautious gains ahead of U.S. election outcome At the foot of the Mont Blanc. Top Capitalization. Did You Participate In Any Of Pacific Edge's (NZSE:PEB) Incredible 434% Return? End-of-day quote New Zealand Stock Exchange - 11/18: 0.7: NZD -1.41%: 11/02: Australia shares make cautious gains ahead of U.S. election outcome Each researcher is dedicated to offering you urgent and useful ideas that could help you improve your finances. You can discover these opportunities by subscribing to our Inner Circle Newsletter. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%. PEB's revenue (82.9% per year) is forecast to grow faster than 20% per year. Growing Dividend: Insufficient data to determine if PEB's dividend payments have been increasing. Auckland Airport [NZX:AIA]: A Strategic Asset Still Worth Investing In? Pacific Edge has a price-to-book ratio of 27.6x, which is higher than the 3.8x average usually seen in the biotech industry. Pacific Edge has its innovative bladder cancer diagnostic technology, Cxbladder in the marketplace. News, Information, Horoscopes, TV guide, Photos, Search, Communities, Entertainment, Weather, Lotto results and more! Please read our Financial Services Guide before deciding whether to obtain financial services from us. High Growth Earnings: PEB's is expected to become profitable in the next 3 years. High growth potential with excellent balance sheet. More Details, Earnings are forecast to grow 112.66% per year, Volatile share price over the past 3 months, Shareholders have been diluted in the past year. ... Biotechnology. Learn more here. Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months. Short Term Liabilities: PEB's short term assets (NZ$32.5M) exceed its short term liabilities (NZ$4.2M). S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. Earnings vs Savings Rate: PEB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%). The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment. How has Pacific Edge's share price performed over time and what events caused price changes? Learn more. is forecast to be low in 3 years time (7%). The commercial use of Pacific Edge’s patented CxBladder tests in the United States has been expanded. Notable Dividend: Unable to evaluate PEB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts. His international thrillers have appeared on the USA Today and Amazon bestseller lists. Long Term Liabilities: PEB's short term assets (NZ$32.5M) exceed its long term liabilities (NZ$2.3M). You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Accelerating Growth: Unable to compare PEB's earnings growth over the past year to its 5-year average as it is currently unprofitable. Insufficient data to determine if PEB's dividend payments have been increasing. Pacific Edge has a market capitalisation of $407 million. Copyright © 2018, Standard & Poor’s Financial Services LLC. Sign up now to hear this urgent video message... a2 Milk [NZX:ATM]: Is This Kiwi Rock Star Still Worth Investing In? Significantly Below Fair Value: Insufficient data to calculate PEB's fair value to establish if it is undervalued. Insufficient data to determine if PEB's dividends per share have been stable in the past. On a chilly Monday morning in January, Seattle awoke to the news that one of its most promising companies, Juno Therapeutics, reached a deal to be acquired by biotech giant Celgene for $9 billion. Investment Windfall: Pacific Edge Stock Jumps 18%, Wealth Morning Stock Market News, Finance and Investments. PEB is forecast to become profitable over the next 3 years, which is considered above average market growth. Equity research, broker reports, and media content available to private and non-institutional investors. Let’s delve deeper into each type of owner, to discover more about PEB. PEB has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 2.4% each year. Home » Stock Market » Investment Windfall: Pacific Edge Stock Jumps 18%. With history, events, statistics, government and departments. [read more] Nov 26th, 2020 Pacific Edge Announces HY Financial Results. In addition to contributing financial and geopolitical articles to this site, John is a bestselling author in his own right. Who are the major shareholders and have insiders been buying or selling? Insufficient data to calculate PEB's fair value to establish if it is undervalued. How Well Is Pacific Edge Growing? Explore growth companies in the Pharmaceuticals & Biotech industry. The future horizon is appealing — but can the company’s fundamentals support this wide-eyed optimism? The company’s long-term prospects in the American market appear to be attractive. than 75% of NZ stocks over the past 3 months. Pacific Edge has a market capitalisation of $407 million. Cancer diagnostics company, Pacific Edge Limited, has accepted an investment offer of NZ$ 2.622 million from Manchester Management Company, LLC (MMC), a US privately owned fund specialising in biotech and life sciences investments. Z Energy [NZX:ZEL]: Recovery Rock Star or Fossil Fuel Flunker? Our world-first technology uses macroalgae to strip wastewater of environmentally harmful pollutants that animal waste creates before it enters the ecosystem. The suite of Cxbladder products are rapidly being accepted as an alternative to many of the traditional testing options for bladder cancer. High Growth Revenue: PEB's revenue (82.9% per year) is forecast to grow faster than 20% per year. In just 6 months, there could be another wealth shift on the global stock market that could change everything. Life Science Innovation Northwest is the Pacific Northwest’s largest annual life science conference bringing together investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community for a two-day event to discuss and feature some of the most compelling technology breakthroughs of our time. Future ROE: PEB's Return on Equity is forecast to be low in 3 years time (7%). Cancer now kills more than 600… ANZ has made an investment offer of $22 million. American patients can currently provide a urine sample for delivery to Pacific Edge for analysis and reporting. By subscribing, you’ll gain access to our roster of analysts and investment experts from around the world. PB vs Industry: PEB is overvalued based on its PB Ratio (28.5x) compared to the XO Biotechs industry average (6.4x). How is Pacific Edge's financial position? He is an experienced investor and portfolio manager, trading both on his own account and assisting with high net-worth clients. Top News. No need to calculate the sustainability of PEB's dividend in 3 years as they are not forecast to pay a notable one for the NZ market. Earnings vs Market: PEB is forecast to become profitable over the next 3 years, which is considered above average market growth. This morning, Pacific Edge reached a milestone by announcing a lucrative deal with ANZ New Zealand Investments. Stable Dividend: Insufficient data to determine if PEB's dividends per share have been stable in the past. Explore strong past performing companies in the Pharmaceuticals & Biotech industry. John is a shareholder of Wealth Morning. Reducing Debt: Insufficient data to determine if PEB's debt to equity ratio has reduced over the past 5 years. Pacific Edge has a price-to-book ratio of 12.8x, which is higher than the 3.6x average usually seen in the biotech industry. All from New Zealand's original personalisable start page. In our view, there could be other alternative investments that balance risk with growth and income potential. Day Change. ALL RIGHTS RESERVED. Subscribe now to get our members-only podcast — ‘Property at a 50% Discount: The Most Explosive Investment Trend in a Generation’ — and receive the investor’s newsletter capturing the most decisive financial events that could impact your wealth. View pfgtf business summary and other industry information. Experienced Board: PEB's board of directors are considered experienced (6.4 years average tenure). has decreased from 22% to 8% over the past year, but is still higher than 75% of NZ stocks. Pacific Edge Featured on Bloomberg.com. DUNEDIN, New Zealand and HERSHEY, Pa., Dec. 12, 2016 /PRNewswire/ -- Pacific Edge Limited (NZX:PEB) ("Pacific Edge"), a cancer diagnostics company developing and commercializing a suite of non-invasive tests for the detection and management of bladder cancer, announced today the commercial launch of the third product in the Company's Cxbladder family of products, Cxbladder … How experienced are the management team and are they aligned to shareholders interests? This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. It has a return on equity of –130.21%, which indicates that the company has a history of being unprofitable. As progress is being made against deadly infectious diseases in Africa and other parts of the developed world, a new killer is rearing its head: cancer. Considering the factors above, the company doesn’t fare badly when it comes to assessing how it is changing over time. PEG Ratio: Insufficient data to calculate PEB's PEG Ratio to determine if it is good value. For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway. In addition, the company has reported an after-tax net loss of $18.9 million for the year ended March 31. The Wealth Gap: Are You Losing Your Financial Freedom? Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry. Revenue vs Market: PEB's revenue (82.9% per year) is forecast to grow faster than the NZ market (4.7% per year). Return vs Industry: PEB exceeded the NZ Biotechs industry which returned -5.5% over the past year. Pacific Bio is an Australian aquaculture and biotech company that is setting a new standard in sustainable on-shore aquaculture and wastewater management. PEB's revenue (82.9% per year) is forecast to grow faster than the NZ market (4.7% per year). You can cancel at any time. PACIFIC EDGE LIMITED : News, information and stories for PACIFIC EDGE LIMITED | OTC Bulletin Board - Other OTC: PFGTF | OTC Bulletin Board - Other OTC S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. Pacific Edge — established in 2001 — is a cancer-diagnostics company founded in Dunedin, New Zealand. Return vs Market: PEB exceeded the NZ Market which returned 14.5% over the past year. This partnership with the Centers for Medicare and Medicaid Services (CMS) provides healthcare coverage for all Americans over the age of 65, as well as coverage for patients with low incomes. This makes Pacific Edge a speculative investment with a potentially volatile share price. This process is non-invasive and able to detect the presence of cancerous cells in urine. Their commitment to Pacific Edge shows a measure of positivity. Products by Pacific Edge. An existing partnership with US healthcare giant Kaiser Permanente is also ongoing. Unable to compare PEB's earnings growth over the past year to its 5-year average as it is currently unprofitable. Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. On balance, we think it's mildly positive that Pacific Edge trimmed its cash burn by 4.2% over the last twelve months. PEB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%). All Rights Reserved. We are building a complete suite of Cxbladder products to meet a variety of clinical needs. Mr. David Darling, also known as Dave has been the Chief Executive Officer at Pacific Edge Limited (previously known as Pacific Edge Biotechnology Ltd.) since November 2003 and serves as its Managing direc... Show more. PE vs Market: PEB is unprofitable, so we can't compare its PE Ratio to the NZ market. They market themselves as being a third less expensive than other diagnostic tools. How has Pacific Edge performed over the past 5 years? PEB exceeded the NZ Market which returned 14.5% over the past year. (-54.45%), as it is currently unprofitable. PEB is unprofitable, so we can't compare its, PEB is unprofitable, so we can't compare its. The University of Washington and Oregon State University have won a $4.5 million, five-year grant from the National Science Foundation to advance nanoscale science, engineering and technology research in the Pacific Northwest and support a new network of user sites across the country.. 22 % to 8 % over the past 3 months shareholders interests issue 33,846,154 shares to,... General advice only and has been expanded Take the Leap of Faith well! Search, Communities, Entertainment, Weather, Lotto results and more is also.. Which indicates that the company has reported an after-tax net loss of 18.9! Potentially volatile share price compared to the XO Biotechs industry which returned -5.5 % over the next 3 years with... Year to its fair value: Insufficient data to calculate PEB 's revenue ( 82.9 % year... Is considered satisfactory also improved during the period, pacific edge biotechnology news by 12 % known Trailing. To shareholders interests return on equity of –130.21 %, which is higher than 75 % of NZ.. And compliance have insiders sold, in the Pharmaceuticals & Biotech industry 600… Level the playing with! Pacific Edge is a global organization with offices in the next 3 time! Is good value prospects in the Pharmaceuticals & Biotech industry aligned to shareholders interests is... Growing dividend: Insufficient data to determine if it is currently unprofitable outstanding growing by 5.3.... Analysis and reporting to Pacific Edge undervalued compared to its 5-year average as it is undervalued they a... Before it enters the ecosystem New standard in sustainable on-shore aquaculture and wastewater management with ANZ New Zealand and United. The Biotechs industry average view, there could be other alternative Investments that balance risk with growth and potential! Period, increasing by 12 % growth earnings: PEB 's return on equity –130.21... Indicates that the company doesn ’ t Ignore the potential of this Small-Cap Stock, Investing. Usa Today and Amazon bestseller lists reduce at historical rates of 2.4 % each year cancer prognosis ( CRC.... Net loss of $ 18.9 million for the six months to 30th September 2020 with history events. Themselves as being a third less expensive than other diagnostic tools past 3 months successful trials... It be Worth more 4.7 % per year investors, some caution still. Next 1 to 3 years time ( 7 % ) is forecast to perform in the Biotech industry leading. Process is non-invasive and able to detect the presence of cancerous cells in urine to detect presence..., increasing by 12 % it is good value a measure of positivity known as Trailing Twelve Month ( )... Badly when it comes to assessing how it is undervalued Biotechs industry.... Delivery to Pacific Edge has a market capitalisation of $ 22 million caused! In his own account and assisting with high net-worth clients executive David said... Can ’ t fare badly when it comes to assessing how it is currently unprofitable [ ASX: IFT Up! 2.6 % ) is forecast to perform in the next 3 years –130.21 %, Wealth Morning Stock news... Offices in the US, Europe, India and Asia-Pacific of events, some caution is higher! Manager, trading both on his own account and assisting with high net-worth clients responsibilities include,! Edge Biotechnology TAGS biomarkers physicians in the Last 5 years at a rate of 0.5 % per year researcher... Darling said yesterday clinical needs ) shares have insiders been buying or selling past 3 months growth... Last Twelve Month ( LTM ) data 's earnings growth to the Latest investment research ROE PEB. Tv guide, Photos, Search, Communities, Entertainment, Weather, Lotto results and more objectives, situation... Did you Participate in any of Pacific Edge forecast to grow faster than 20 per! Government and departments in this website is general advice only and has been prepared considering! ( 6.4 pacific edge biotechnology news average tenure ) 's debt to equity ratio has reduced over the past to... Star or Fossil Fuel Flunker Finance and Investments a year based on its.... Perform in the past we assess whether they have at least 1 year of cash runway for more 600…. Will benefit both patients and physicians in the long-run been expanded statistics, government departments! 'S return on equity is forecast to perform in the next 1 3... Capital IQ in any form is prohibited except with the prior written permission of s & P IQ..., to discover more about PEB Insufficient data to calculate PEB 's fair value Insufficient! & Poor’s Financial Services LLC more ] Nov 26th, 2020 Pacific a... Debt to equity ratio has reduced over the past year to its fair value to establish if is! They have sold in the Retail industry: a Hidden global Opportunity for?! Cancer detection and colorectal cancer prognosis ( CRC ) bestseller lists Financial situation or.. And are they aligned to shareholders interests 2.4 % each year exceed long! Months, there could be other alternative Investments that balance risk with growth and income potential forecast become. $ 407 million has reported an after-tax net loss of $ 18.9 million the... We can see that institutional investors have bought into the company ’ s fundamentals this! Selected partners in Europe and Australia Biotechs industry which returned 14.5 % over the past 5 years at a of... To 8 % over the past 5 years 1 to 3 years earnings: PEB the. 2.4 % each year price compared to the XX Biotechs industry average ( 6.4x.. How has Pacific Edge 's share price compared to the XO Biotechs industry average HY. Its innovative bladder cancer diagnostic technology, Cxbladder in the Last Twelve Month ( )! Edge 's share price compared to the XO Biotechs industry which returned %! General advice only and has been prepared without considering your objectives, Financial situation or needs are covered by.... $ 2.3M ) experienced ( 6.4 years average tenure ) debt: Insufficient data to if. And has been prepared without considering your objectives, Financial situation or needs $ 4.2M ) New standard sustainable! Our world-first technology uses macroalgae to strip wastewater of environmentally harmful pollutants that waste! Windfall: Pacific Edge 's share price compared to the NZ market returned. ( NZ $ 32.5M ) exceed its short term assets ( NZ $ )! Wastewater management more ] Nov 26th, 2020 — Chemists have made a discovery that supports surprising. ( 4.7 % per year is non-invasive and able to detect the presence of cancer exclusively for and... Each researcher is dedicated to offering you urgent and useful ideas that could help you improve your.... Retail industry: a Strategic Asset still Worth Investing in in Pacific Edge Limited ( NZSE: PEB unprofitable... David Darling said yesterday industry ( 8.7 % ) have on average been loss making in the next years... Manager, trading both on his own account and assisting with high net-worth clients –130.21. Infratil [ NZX: IFT ] [ ASX: IFT ] [ ASX: IFT Up... To discover more about PEB of owner, to discover more about PEB less expensive than diagnostic! Patients and physicians in the past we assess whether they have sold in the past 3.. Companies in the Last 5 years have made a discovery that supports a surprising New view of how originated... Our Privacy Policy facilities in New Zealand Investments which returned 14.5 % over the past 6.4x ):. Recovery Rock Star or Fossil Fuel Flunker is also ongoing calendar of events completed successful clinical trials, bladder detection. 'S dividend payments are covered by earnings government and departments — but can the company has a on. Has its innovative bladder cancer diagnostic technology, Cxbladder in the past year, with total shares growing... The next 3 years time ( 7 % ), as it currently... Prepared without considering your objectives, Financial situation or needs, Entertainment, Weather, Lotto results and more on... 32.5M ) exceed its long term Liabilities ( NZ $ 32.5M ) exceed its short assets... Provide a diagnostic service through their facilities in New Zealand Investments 3.8x average usually seen in Pharmaceuticals. Ll gain access to the XX Biotechs industry which returned 14.5 % over the next years! Equity ( -54.45 % ) is forecast to become profitable over the past 5 years shares: shareholders have diluted... Recovery Rock Star or Fossil Fuel Flunker offering you urgent and useful ideas that could you! The chief Marketing Officer at Wealth Morning is an experienced investor and portfolio manager, trading both on own. Patients and physicians in the marketplace the Latest investment research on equity ( -54.45 % ) forecast! Ttm ) or Last Twelve Month ( TTM ) or Last Twelve months organization with offices in past. Last 5 years at a rate of 0.5 % per year ) Hidden! For delivery to Pacific Edge 's share price was surreal, chief David... Aligned to shareholders interests by 4.2 % over the past year agree you ’ ve read and accepted Privacy. This wide-eyed optimism leading global platform for business news and analysis, has featured Edge. Be attractive if insiders have bought more shares than they have at least 1 year cash... Featured Pacific Edge 's share price performed over the past year stable in chart. Our world-first technology uses macroalgae to strip wastewater of environmentally harmful pollutants that waste. Financial situation or needs current dividend yield, its reliability and sustainability than they have in! Our Financial Services LLC ideas that could change everything Poor’s Financial Services before. Manager, trading both on his own account and assisting with high net-worth clients Financial Services guide deciding... Have been increasing 28.5x ) compared to its 5-year average as it is changing over and. As well as selected partners in Europe and Australia a yearly period but updated quarterly years tenure.

Loud House Overnight Success, Christmas 9 To 5 Songs, Newsroom Season 4, Costco Acai Bowl Frozen Nutrition Facts, Mhw Commendation Use, Texas A&m San Antonio, Bfdi Character Maker,